Assertio Therapeutics, Inc.
Records under this name other than patents Assertio Therapeutics, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Back to Assertio Therapeutics, Inc.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,662,858 | Method of Treating Post-Surgical Acute Pain Formerly held In force · High confidence | In force | High confidence | |
| US 7,884,095 | Method of Treating Post-Surgical Acute Pain Formerly held In force · High confidence | In force | High confidence | |
| US 7,939,518 | Method of Treating Post-Surgical Acute Pain Formerly held In force · High confidence | In force | High confidence | |
| US 8,110,606 | Method of Treating Post-Surgical Acute Pain Formerly held In force · High confidence | In force | High confidence | |
| US 9,561,200 | Method of Treating Post-Surgical Acute Pain Formerly held In force · Medium confidence | In force | Medium confidence | |
| US 8,623,920 | Method of Treating Post-Surgical Acute Pain Formerly held In force · Medium confidence | In force | Medium confidence | |
| US 8,329,750 | Methods for Treating Vasomotor Symptoms Using Gaba Analogs in a Gastric Retentive Dosage Form Formerly held In force · Medium confidence | In force | Medium confidence | |
| US 9,301,934 | Gastric Retentive Dosage Forms for Extended Release of Acamprosate into the Upper Gastrointestinal Tract Lapsed on the fee record Ended Apr 5, 2024 · High confidence | Lapsed on the fee record | Ended Apr 5, 2024 | High confidence |
| US 7,438,927 | Methods of Treatment Using a Gastric Retained Gabapentin Dosage Formerly held Term ended Term ended Feb 26, 2024 · High confidence | Term ended | Term ended Feb 26, 2024 | High confidence |
| US 9,161,911 | Gastric Retentive Pharmaceutical Compositions for Treatment and Prevention of CNS Disorders Lapsed on the fee record Ended Oct 20, 2023 · High confidence | Lapsed on the fee record | Ended Oct 20, 2023 | High confidence |